Hanmi Pharm. Co., Ltd.
Research Hanmi Pharm. Co., Ltd. (128940.KS) on Bullrun: market cap KRW 6.46T, dividend yield 0.4%. Explore financials, valuation history, model signals, and stock context.
Key Metrics
- Ticker128940.KS
- ExchangeKS
- CountrySouth Korea
- SectorHealthcare
- IndustryDrug Manufacturers - Specialty & Generic
- CurrencyKRW
- Market capKRW 6.46T
- Dividend yield0.4%
- Financial periodQ2 2026
- RevenueKRW 467.25B
- Net incomeKRW 83.31B
- Free cash flowKRW 76.45B
- Gross margin64.9%
Valuation Snapshot
latest market cap is KRW 6.46T; dividend yield is 0.4%.
Peer valuation comparison
Latest dividend yield is 0.39% versus a Healthcare sector median of 2.4% (83.7% below).
Valuation history
| Year | Snapshot date | Market cap | P/E | Dividend yield | Annual dividend/share |
|---|---|---|---|---|---|
| 2026 | 2026-11-11 | KRW 6.46T | n/a | 0.4% | 2000 |
Dividend history
Latest trailing dividend snapshot: annual dividend/share 2000 KRW, yield 0.4%.
About Hanmi Pharm. Co., Ltd.
Hanmi Pharm. Co., Ltd., a biopharmaceutical company, engages in the manufacture and sale of pharmaceutical products in South Korea, China, Japan, the United States, and internationally. It focuses on research areas with high unmet medical needs, including obesity, metabolism, oncology, and rare diseases.
ETFs that hold Hanmi Pharm. Co., Ltd.
US-listed ETFs
Hanmi Pharm. Co., Ltd. is held by 40 US-listed ETFs, going by the latest portfolios they filed with the SEC. The 8 most traded of them:
| ETF | Weight | Fee |
|---|---|---|
| iShares Core MSCI Emerging Markets ETF (IEMG) | 0.01% | 0.09% |
| Vanguard FTSE Developed Markets Index Fund ETF Shares (VEA) | <0.01% | 0.03% |
| Vanguard Total International Stock Index Fund ETF Shares (VXUS) | <0.01% | 0.05% |
| Vanguard Total World Stock Index Fund ETF Shares (VT) | <0.01% | 0.06% |
| Schwab International Equity ETF (SCHF) | 0.01% | 0.03% |
| Vanguard FTSE All-World ex-US Index Fund ETF Shares (VEU) | <0.01% | 0.04% |
| iShares Core MSCI Total International Stock ETF (IXUS) | <0.01% | 0.07% |
| Avantis Emerging Markets Equity ETF (AVEM) | 0.01% | 0.33% |
Portfolios as filed with the SEC on Form N-PORT, dated May to July 2026. Brokers in the EU generally do not offer US-listed ETFs to retail investors.
Related stock research
Other Healthcare stocks
Frequently asked questions
What is Hanmi Pharm. Co., Ltd.'s market cap?
Hanmi Pharm. Co., Ltd.'s market capitalization is KRW 6.46T.
Does Hanmi Pharm. Co., Ltd. pay a dividend?
Hanmi Pharm. Co., Ltd. has a dividend yield of 0.4%.
What does Hanmi Pharm. Co., Ltd. do?
Hanmi Pharm. Co., Ltd., a biopharmaceutical company, engages in the manufacture and sale of pharmaceutical products in South Korea, China, Japan, the United States, and internationally. It focuses on research areas with high unmet medical needs, including obesity, metabolism, oncology, and rare diseases. The company's products include Gugutams, a urological combination therapy combining two active ingredients: tamsulosin, a treatment for Obstructive Prostatic Growth (OPG), and tadalafil, a treatment for erectile dysfunction (ED).